11 unknown, 9 recruiting, 5 not yet recruiting, 1 active not recruiting. 14 Phase 2, 3 Phase 1, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Unknown 7, Not yet recruiting 4, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 3 | Unknown 2, Recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Unknown 1 |
Follow PD-1: new trials by email Literature Review of PD-1 trials Research Report on PD-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab - Hepatocellular Carcinoma (HCC), Immunotherapy | Phase 2 | Not yet recruiting | Anhui Provincial Hospital | 47 | 2025-08-20 | 2025-08-17 |
| A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma Radical surgery, TACE treatment, Iparomlimab and Tuvonralimab Injection (QL1706) - Hepatocellular Carcinoma, Immunotherapy | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 48 | 2025-08-11 | 2025-08-20 |
| PD-1 Inhibitor Therapy Versus Radiotherapy in MPR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-006) PD-1inhibitor, radiotherapy - HNSCC, PD-1 | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 50 | 2025-08-01 | 2025-07-29 |
| A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer PSQI, PQSI - Lung Cancer (NSCLC), Sleep Disorders, Circadian Rhythm | Not yet recruiting | Shanghai Zhongshan Hospital | 350 | 2025-06-01 | 2025-05-01 | |
| Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）, Maintenance treatment (after 3 months): fruquintinib+PD-1 - Gastric Adenocarcinoma, GEJ Adenocarcinoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 55 | 2025-03-31 | 2025-03-21 |
| Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer transfusion of 5×10^8 PD-1 knockout TILs per kg body weight, transfusion of 1×10^9 PD-1 edited TILs per kg body weight, transfusion of 2×10^9 PD-1 edited TILs per kg body weight - Colorectal Cancer (CRC), Tumor Infiltrating Lymphocytes | Phase 1 | Recruiting | Ruijin Hospital | 29 | 2024-12-31 | 2025-06-24 |
| Tirellizumab Combined With TP Neoadjuvant Therapy in the Treatment of Early Oral Squamous Cell Carcinoma （HNC-SYSU-005） Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery, Traditional surgery - HNSCC, PD-1 | Phase 2 | Active not recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 60 | 2024-12-15 | 2025-12-05 |
| HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Recruiting | First Hospital of China Medical University | 84 | 2024-09-16 | 2024-10-08 | |
| A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. Cancer, Immunotherapy | Recruiting | Oxford Biodynamics Inc. | 2000 | 2024-05-14 | 2025-03-17 | |
| LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer LM-108 antibody and sintilimab, LM-108 antibody and sintilimab and chemotherapy - NSCLC, PD-1 | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 50 | 2024-01-12 | 2024-06-28 |
| Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004) PD-1 with chemotherapy, upright surgery - Oral Cancer, PD-1 | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 40 | 2023-09-01 | 2023-11-14 |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
| 4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses, Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses - HNSCC, Oral Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 192 | 2023-04-04 | 2023-09-07 |
| A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) F520, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer, NSCLC | Phase 2 | Unknown | Shandong New Time Pharmaceutical Co., LTD | 84 | 2023-03-01 | 2023-02-24 |
| PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy PD-1inhibitor, concurrent chemoradiotherapy - HNSCC, Radiotherapy | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 324 | 2023-01-01 | 2023-08-08 |
| Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma DNA panel and RNA Sequencing - Locally Advanced Gastric Adenocarcinoma, PD-1 | Completed | Xijing Hospital | 28 | 2022-07-18 | 2025-12-04 | |
| PD-1 Antibody for Reactive EBV After BMT toripalimab injection - PD-1, EBV Infection | Early Phase 1 | Unknown | Beijing Friendship Hospital | 20 | 2021-07-01 | 2021-06-29 |
| Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors blood draw and questionnaire completion, questionnaire completion, blood collection - Thyroid, PD-1 | Recruiting | Icahn School of Medicine at Mount Sinai | 17 | 2021-06-09 | 2026-03-27 | |
| Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer Sintilimab - Tislelizumab, Locally Advanced Rectal Cancer | Phase 1 | Unknown | The First Hospital of Jilin University | 46 | 2021-06-01 | 2023-11-18 |
| A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study Tislelizumab - Head and Neck Cancer, Radiation | Phase 2 | Unknown | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 38 | 2021-04-01 | 2021-03-24 |
Showing 20 of 27. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Hepatocellular (2) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Microsatellite Instability (2) · Mouth Neoplasms (2) · Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Colorectal Neoplasms (1) · Epstein-Barr Virus Infections (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Recurrence (1) · Sleep Disorders, Circadian Rhythm (1)
Neoplasms (15) · Neoplasms by Site (15) · Carcinoma (8) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Head and Neck Neoplasms (6) · Carcinoma, Squamous Cell (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Lung Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Respiratory Tract Diseases (3)
toripalimab (4) · sintilimab (3) · Carboplatin (2) · Drug Therapy (2) · lenvatinib (2) · Bevacizumab (1) · Blood Specimen Collection (1) · Chemoradiotherapy (1) · Dasatinib (1) · Paclitaxel (1) · Pemetrexed (1) · RC48 antibody (1) · Radiotherapy (1) · Sequence Analysis, RNA (1) · disitamab vedotin (1)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5) · Lei Li (2) · Ruijin Hospital (2) · Anhui Provincial Hospital (1) · Beijing Friendship Hospital (1) · First Hospital of China Medical University (1) · Guohui Li (1) · Icahn School of Medicine at Mount Sinai (1) · Oxford Biodynamics Inc. (1) · Peking University (1) · RenJi Hospital (1) · Shandong New Time Pharmaceutical Co., LTD (1) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Shanghai Zhongshan Hospital (1)
China (21) · United States (2)
Chunxia Su, Phd (1) · Haige Chen (1) · Lei Li (1) · Lei Li, M.D. (1) · Ming-Yuan Chen, MD, PhD (1) · Philip Friedlander, MD PhD (1) · Ryan Mathis, MD (1) · Xuehao Wang (1) · Yongheng Li, MD (1) · Yongxiang Xia (1) · Zhao Wang (1) · Zilong Liu (1) · Ziyu Li, MD (1)